Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.97M | -2.12M | -2.14M | -2.20M | -2.42M |
| Total Depreciation and Amortization | 97.90K | 99.50K | 101.20K | 102.40K | 103.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 72.10K | 79.20K | 88.20K | 87.20K | 507.00K |
| Change in Net Operating Assets | -24.60K | -113.60K | 60.50K | 309.10K | 448.60K |
| Cash from Operations | -1.82M | -2.05M | -1.89M | -1.70M | -1.36M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 2.56M | 2.96M | 2.91M | 2.37M | 1.37M |
| Total Debt Repaid | -165.40K | -162.10K | -158.80K | -155.50K | -183.80K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.76M | 2.06M | 2.03M | 1.64M | 884.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -62.30K | 12.30K | 146.70K | -58.60K | -480.40K |
